3-Monoacetylmorphine

• none

• AU: S9 (Prohibited substance)
• UK: Class A
• US: Schedule I

• 3-acetyl-6-hydroxy-(5α,6α)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan

• 5140-28-3 ^Y

• 5462504

• 4575431 ^Y

• 9N7243EY5T

• DTXSID30183774

• Interactive image

• CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1

• InChI=1S/C19H21NO4/c1-10(21)23-15-6-3-11-9-13-12-4-5-14(22)18-19(12,7-8-20(13)2)16(11)17(15)24-18/h3-6,12-14,18,22H,7-9H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1 ^Y
• Key:GMLREHXYJDLZOU-LEPYJNQMSA-N ^Y

References

1. ^ Houdi AA, Kottayil S, Crooks PA, Butterfield DA (March 1996). "3-O-acetylmorphine-6-O-sulfate: a potent, centrally acting morphine derivative". Pharmacology, Biochemistry, and Behavior. 53 (3): 665–671. doi:10.1016/0091-3057(95)02067-5. PMID 8866970. S2CID 14870642.
2. ^ Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA (August 2006). "Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners". Bioorganic & Medicinal Chemistry Letters. 16 (16): 4291–4295. doi:10.1016/j.bmcl.2006.05.060. PMID 16777416.
3. ^ Brock CP, Kottayil S, Butterfield DA, Crooks PA (January 1996). "A Dihydromorphine-6-O-sulfate". Acta Crystallographica Section C. 52 (1): 122–5. doi:10.1107/S0108270195010250.